The bioefficacy of a novel VECTRON™ T500 indoor residual spray formulation in an experimental huts trial against Anopheles gambiae s.l. populations.

ABSTRACT

BACKGROUND: The emergence of insecticide resistance and its spread through populations of malaria vectors has decreased the number of insecticides available for control. Insecticide resistance has been observed in vector populations across sub-Saharan Africa in malaria endemic areas. Therefore, new compounds with different modes of action are needed that can be used in the management of resistance. The current study assessed the bioefficacy of the new indoor residual spray formulation, VECTRON™ T500 against Klypson 500 WG and water against laboratory reared and wild populations of Anopheles gambiae s.l.. The comparative experimental hut trial was implemented between June 2022 and December 2022 to determine the efficacy of VECTRON™ T500, containing the active ingredient (ai) broflanilide as a 50 % wettable powder (WP). The efficacy of VECTRON™ T500 was compared with a positive control, Klypson 500 WG, a wettable granule (WG) formulation that contains 50 % clothianidin. Cement and mud walls were sprayed with VECTRON™ T500, Klypson 500 WG with water sprayed as a negative control. The two insecticides and negative control were evaluated monthly for six months against laboratory and the field-derived An. gambiae s.l. using the standard WHO cone bioassays. Each wall had two cones on each day of testing. VECTRON™ T500 was sprayed on both surface types at a rate of 100mg ai/m2 whilst Klypson 500 WG was applied at a rate of 300 mg ai/m2. For both wall surface types, the vector from the laboratory-reared and the wild populations exhibited a low knockdown effect to both VECTRON™ T500 and Klypson 500 WG. A total of 3,840 mosquitoes were used of which 2,880 (75 %) were susceptible colony of An. gambiae s.s. and 960 (25 %) were wild An. gambiae s.l.. The VECTRON™ T500 induced a mortality of 97.8 %-98.1 % in the laboratory population and 83.2-95.0 % wild population mosquitoes on cement and mud-walled huts respectively while Klypson 500 WG ranged from 89.6-99.0 % for wild and 99.0-99.3 % for the laboratory population mosquitoes on cement and mud walls respectively. The knockdown due to VECTRON™ T500 was 7.08 % in the sixth month, while for Klypson 500 WG was 16.04-17.50 %. The monthly wall cone bioassay mortality with VECTRON™ T500 remained over 80 % for 6 months post-spraying for both laboratory and wild populations. The findings of this study have shown VECTRON™ T500 to have extended efficacy against malaria vector mosquitoes when applied to cement and mud walls. The evaluated new IRS formulation, VECTRON™ T500, performed equally with the positive control, Klypson 500 WG, regarding its impact on vector mortality.